An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.Arvind Dasari,John S. Kauh,Christopher Tucci,Shivani Nanda, Marek K. Kania, Jennifer W. Carlisle,Andrew Scott PaulsonJOURNAL OF CLINICAL ONCOLOGY（2021）引用 1|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
